MedDataX Logo

Inventory of the Management of Acute Community-acquired Pneumonia in Strasbourg University Hospitals

NCT ID: NCT05661513

Last Updated: 2023-12-19

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

1000 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-09-09

Study Completion Date

2025-03-09

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Acute community-acquired pneumonia (CAP) refers to an acute infection of the lung parenchyma, occurring within the first 48 hours of hospitalization. It is a frequent, serious pathology with a strong economic impact. Viruses (rhinovirus, respiratory syncitial virus, influenza virus for the most common) and Streptococcus pneumoniae are the most frequently encountered pathogens. However, more than half of the PACs have no microbiological documentation. The management of CAPs is based on national and international recommendations. Several studies have shown imperfect compliance by clinicians with recommendations with a prognostic impact.

The various published studies insist on the variability of the incidence, the type of pathogen, the severity and the economic impact, depending on the series. They also insist on the need to know the local epidemiology, in particular microbiological, in order to adapt the recommendations.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The objective of the study is to determine the epidemiological, clinical, biological and imaging characteristics of people admitted for acute community-acquired pneumonia.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Infection, Lung Parenchyma

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Community-acquired Pneumonia Infection, Lung parenchyma Rhinovirus Respiratory syncitial virus Influenza virus Streptococcus pneumoniae

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

RETROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Adult subject (≥ 18 years old),
* acute community-acquired pneumonia (\< 48 hours after admission),
* admitted from the Emergency Department, consultation or home.
* Subject not objecting to the reuse of their data for scientific research purposes

Exclusion Criteria

* Expressed refusal to reuse data for scientific research purposes.
* bronchitis, acute nosocomial pneumopathy, secondary infection due to bronchial dilation.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University Hospital, Strasbourg, France

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Service de Pneumologie - CHU de Strasbourg - France

Strasbourg, , France

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

France

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Loïc KASSEGNE, MD

Role: CONTACT

Phone: 33 3 69 55 01 88

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Loïc KASSEGNE, MD

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

8718

Identifier Type: -

Identifier Source: org_study_id